Recent Updates
Recently added Catalysts

GEN1057

Phase 1

Advanced Malignant Solid Tumors | Small molecule | Oncology |Genmab A/S|Last Updated: Mar 2, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment45
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06573294Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid TumorsPHASE1 RECRUITING 45 — — Aug 1, 2024Sep 1, 2027Mar 2, 2026 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
GEN1057DRUGIntravenous (IV) infusion
PremedicationDRUGIV infusion/orally by mouth.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06573294studyFirstPostDate: changed